Guidant Corp.
Positive 6-month results reported for SPIRIT FIRST trial
Published in Cardiovascular Business Week, October 26th, 2004
SPIRIT FIRST is a prospective, randomized, single-blind trial evaluating Guidant's MULTI-LINK VISION-based everolimus eluting coronary stent system utilizing a durable polymer versus an uncoated MULTI-LINK VISION Coronary Stent System control in de novo (previously untreated) lesions.
Angiographic in-stent late loss at 6 months, the study's primary endpoint, was 0.10 mm for the MULTI-LINK VISION-based everolimus eluting stent system and 0.84 mm for the control arm. The in-stent angiographic binary restenosis rate for the everolimus...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- CardioDynamics
Device firm reports 25th quarter of revenue growth - CardioVascular BioTherapeutics, Inc.
Biopharmaceutical firm files registration statement for IPO - Diomed Holdings, Inc.
EVLT maker agrees to $10.6M financing - Lifestream Technologies, Inc.
Cholesterol monitor developer announces 169% increase in July shipments - Morton Grove Pharmaceuticals
FDA clears Cyclosporine Oral Solution, USP, 100 mg/ml for marketing - Nanobac Life Science, Inc.
Life sciences company completes financing - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
